AMD3465 hexahydrobromide

Catalog No.S2879

For research use only.

AMD3465 is a monomacrocyclic CXCR4 antagonist.

AMD3465 hexahydrobromide Chemical Structure

CAS No. 185991-07-5

Purity & Quality Control

Choose Selective CXCR Inhibitors

Other CXCR Products

Biological Activity

Description AMD3465 is a monomacrocyclic CXCR4 antagonist.
CXCR4 [1]
In vitro

AMD3465 blocks the binding of CXCL12 with IC50 of 18 nM in SupT1 cells. AMD3465 inhibits CXCL12-induced calcium signaling in SupT1 cells with IC50 of 17 nM and also inhibits MAPK phosphorylation. While AMD3465 couldn't block the intracellular calcium fluxes elicited by the CCR5 ligands RANTES, LD78β and MIP-1β in U87.CD4.CCR5 cells. AMD3465 suppresses CXCL12-induced chemotaxis of human T-lymphoid SupT1 cells and prevents chemokine-induced internalization of CXCR4 in U87.CD4 cells. Moreover, AMD3465 proves active against the X4 HIV-1 strains IIIB, NL4.3, RF and HE with IC50 from 6-12 nM. AMD3465 suppresses the HIV-2 strains ROD and EHO with IC50 of 12.3 nM. [1] AMD3465 inhibits SDF-1αligand binding with Ki of 41.7 nM sing the CCRF-CEM cell line. Inhibition of CXCR4 signaling pathways by AMD3465 is demonstrated by inhibition of SDF-1α stimulated calcium flux and GTP binding with IC50 of 12.07 nM and 10.38 nM, respectively. Furthermore AMD3465 is able to inhibit CXCR4-mediated physiological response, cell chemotaxis, with IC50 of 8.7 nM. In addition, AMD3465 has no inhibitory effect on either MIP1α, MCP-1, TARC, RANTES, MIP-3β, or IP10 mediated calcium flux, ligands for CCR1, CCR2b, CCR4, CCR5, CCR7 and CXCR3 respectively, or LTB4 binding to BLT1, thus indicating that AMD3465 is a selective inhibitor of CXCR4 over other chemokine receptors. In a separate study AMD3465 is shown to inhibit SDF-1-mediated CXCR4 internalization in cells expressing GFP-linked CXCR4, and does not cause receptor internalization when incubated with the cells alone. [2]

In vivo The pharmacokinetics of AMD3465 is investigated in mice and dogs. Absorption is rapid following subcutaneous administration. AMD3465 is cleared from dog plasma in a biphasic manner with a terminal half-life of 1.56-4.63 h. AMD3465 shows 100% bioavailability following subcutaneous administration by comparison of exposure to the intravenous and subcutaneous doses. AMD3465 causes leukocytosis when administered subcutaneously in mice and dogs, with peak mobilization occurring between 0.5 h and 1.5 h following subcutaneous dosing in mice and with maximum peak plasma concentration of compound preceding peak mobilization in dogs, indicating that AMD3465 has the potential to mobilize hematopoietic stem cells. [2] AMD3465 abrogates type-2 granuloma formation and eosinophil mobilization at the 6 and 30 mg/kg doses. AMD3465 treatment could cause an ~90% reduction in CXCR4 transcript levels in lungs with type-2 lesions. [3]

Protocol (from reference)

Animal Research:[2]
  • Animal Models: Male Swiss Webster mice
  • Dosages: 5, 10, 20, 50 and 100 mg/kg
  • Administration: Subcutaneous injection
  • (Only for Reference)

Solubility (25°C)

In vitro

Water 98 mg/mL
(109.36 mM)
DMSO 2 mg/mL
(2.23 mM)
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 896.07


CAS No. 185991-07-5
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy AMD3465 hexahydrobromide | AMD3465 hexahydrobromide supplier | purchase AMD3465 hexahydrobromide | AMD3465 hexahydrobromide cost | AMD3465 hexahydrobromide manufacturer | order AMD3465 hexahydrobromide | AMD3465 hexahydrobromide distributor